AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRES
ENSAYO CLINICO COMERCIAL
Información del ensayo clínico
- Promotor: PFIZER, S.L.U.
 - Fase: III
 - Comienzo de la ejecución: 03/08/2021
 - Fin de la ejecución: 30/09/2022
 - IP: JUAN PASQUAU LIAÑO